ClinicalTrials.gg

Program

NNC0442-0344

A development code. Also written as “NNC0442-0344 A”.

Its studies are mostly in Hemophilia A, led by Novo Nordisk.

Furthest: phase 1, since Oct 14, 20243 company-led studies, 1 open or runningNext primary completion: Feb 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk31 open or runningphase 1since Oct 14, 2024Oct 14, 2024Feb 5, 2027phase 1 · NCT07220564

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2024First study: phase 1 study in Hemophilia AFirst studyNCT06649630 · 95 enrolled · Germany
  2. Oct 22, 2025Phase 1 study in Hemophilia ANCT07220564 · 30 planned · United States, Austria, Belgium and more
  3. Nov 16, 2025Phase 1 study in Hemophilia ANCT07238816 · 80 enrolled · United States

Ahead

  1. Feb 5, 2027Primary completion: phase 1 study in Hemophilia ANCT07220564

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07238816Hemophilia A · United States1CompletedMay 8, 202680
NCT07220564Hemophilia A · United States, Austria, Belgium and more1RecruitingFeb 5, 202730
NCT06649630Hemophilia A · Germany1CompletedMar 26, 202695

How it is read

Names in the registry

  • “NNC0442-0344 A”, 3 entries

Codes read as this program: NNC04420344.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.